益气活血中药促血管生成的信号转导机制研究及相关文献评价
|
摘要
治疗性血管新生已经成为缺血性疾病研究领域的热点,益气活血中药治疗冠心病的历史悠久,疗效显著,其促进血管新生,改善心肌供血,已经通过临床和实验研究得到证实,因此益气活血中药促血管新生可能是其治疗冠心病的重要机制之一。本研究通过探讨益气活血中药促大鼠缺血心肌血管新生的分子机制,揭示其干预血管生成的作用和分子靶标,为其防治缺血性疾病提供实验依据。
本论文分为三部分：基础研究、临床文献系统评价和文献综述。
一、基础研究包括以下三部分：
实验一：益气活血中药对大鼠缺血心肌的促血管生成作用
目的：观察益气活血中药人参三七组方促进大鼠缺血心肌血管新生的作用。方法：100只Wistar大鼠随机分为空白组、假手术组、模型组、倍他乐克组和大、小剂量人参三七组方组。采用冠状动脉结扎法建立大鼠急性心梗模型,并于造模后予相应药物治疗12 d。观察各组心肌细胞形态学改变,检测血清血管内皮细胞生长因子(VEGF)的表达；采用Ⅷ因子及CD105抗体检测微血管密度。结果：人参三七组方能够减轻心肌细胞变性,减少炎症细胞,增加微血管密度,提高血清VEGF的浓度。结论：人参三七组方能够保护缺血心肌细胞,具有良好促进急性心梗后大鼠缺血心肌的微血管新生,增加缺血心肌微血管密度的作用。
实验二：益气活血中药对大鼠缺血心肌VEGFR-2和HIF-1α表达的影响
目的：探讨益气活血中药人参三七组方对AMI大鼠缺血心肌VEGFR-2和HIF-1α表达的影响。方法：造模及处理方法同实验一,给药结束后,蛋白免疫印迹法检测缺血心肌的VEGFR-2和HIF-1α的蛋白表达,实时聚合酶链式反应法检测缺血心肌VEGFR-2、HIF-1αmRNA表达。结果：大、小剂量人参三七组方组及倍他乐克组VEGFR-2、HIF-1α蛋白和mRNA表达均显著高于模型组(P＜0.05)；大、小剂量组之间比较,差异亦有统计学意义。倍他乐克组VEGFR-2、HIF-1α蛋白和mRNA高于大、小剂量人参三七组方组(P<0.01)。结论：人参三七组方能够促进缺血心肌VEGFR-2、HIF-1α表达,从而改善心肌缺血,促进侧支循环的形成,具有一定剂量依赖性。
实验三：益气活血中药对Ras下游信号转导通路的影响
目的：观察益气活血中药人参三七组方对Ras信号通路的影响,探讨益气活血中药促进血管新生的信号转导途径。方法：造模及处理方法同实验一,给药结束后,蛋白免疫印迹法检测缺血心肌中Ras.c-Raf-1.ERK1／2及p-ERK1／2的蛋白表达,实时聚合酶链式反应法检测缺血心肌Ras. c-Raf-1、ERK1、ERK2 mRNA表达。结果：各组ERK1／2蛋白表达无显著性差异,大、小剂量人参三七组方组及倍他乐克组Ras.c-Raf-1、p-ERK1／2蛋白和Ras.c-Raf-1、ERK1／2mRNA表达均显著高于模型组(P＜0.05)。结论：人参三七组方能够促进缺血心肌Ras信号通路上的Ras.c-Raf-1及ERK1／2表达,说明人参三七组方可能通过Ras信号通路来促进血管新生。
二、临床文献系统评价：对1994年-2009年在科技期刊上公开发表的益气活血中成药治疗不稳定心绞痛的临床文献进行系统评价。
目的：对益气活血中成药治疗不稳定心绞痛临床研究进行系统评价。方法：①以中文标题：不稳定性心绞痛and(全部检索条目：中医or中药or中西医结合)and(全部检索条目：益气or活血)的检索式检索中国生物医学文献光盘数据库,年限为1994年1月至2009年12月。②由2位研究者按照文献纳入、排除标准独立进行文献筛选,意见不同者通过讨论解决。③获取文献的相关研究特征资料,并加以评价。④对合格的随机对照试验,进行定量的Meta分析。结果：①共检索到170个文献。②经两次筛选,剔除不符合要求以及重复报道的文献,最终共有17篇文献入选评价。③对17篇文献进行Meta分析,总病例数1644例。④益气活血中成药包括愈心痛胶囊、通心络胶囊、复方丹参滴丸(片)、舒心益脉胶囊、步长稳心颗粒、活血通脉胶囊、血府逐瘀胶囊。Meta分析显示,加用益气活血中成药干预对不稳定心绞痛患者心绞痛症状和心电图的改善较单纯西医基础治疗明显提高,能减少硝酸甘油的用量,显著降低血浆内皮素(ET)、血浆内α-颗粒膜蛋白(GMP-140)等与动脉粥样硬化斑块稳定相关指标。结论：益气活血中成药干预不稳定心绞痛在改善心绞痛的症状、心电图表现,减少硝酸甘油的用量以及降低ET、GMP-140方面有一定的疗效。但由于纳入研究的质量不高,还有待进一步研究。
三、文献综述部分通过对123篇文献的梳理和总结,探讨和综述了VEGF、CD105与血管新生的关系及其研究进展,并对益气活血法促冠心病血管新生的研究文献进行了初步总结,提出今后应临床研究与体内外实验研究相结合,从多途径、多环节探讨中药促进冠心病缺血心肌血管新生的作用及信号转导机制。
本研究以Ras蛋白信号通路为主线,观察人参、三七组方对血管生成过程中Ras信号转导系统的干预作用及其机制,属于中医药防治冠心病研究领域的原创性研究工作；借鉴CD105检测肿瘤微血管密度的方法,采用CD105检测缺血心肌的微血管密度,是检测指标的创新应用。
Therapeutic angiogenesis in ischemic diseases has become a hot topic. The Chinese medicine of Tonifying Qi and Activating Blood has a long history and certain efficacy in treating coronary heart disease(CHD). It can improve myocardial ischemic and angiogenesis of myocardial ischemia, and it has been confirmed by a lot of clinical and experimental studies, suggesting that promoting angiogenesis may be one of important mechanisms of Chinese medicine in the treatment of CHD.This study is to probe the molecular mechanism that the Chinese medicine of Tonifying Qi and Activating Blood to promote angiogenesis in myocardial ischemia rats,to reveal the role of intervention in angiogenesis and molecular targets and provide experimental evidence for the prevention and treatment of ischemic disease.
The research includes three parts:experimental research, systematic review and literature review.
1. Experimental research This part includes 3 experiments:
The 1st experiment:Stimulating angiogenesis effect of the Chinese medicine of Tonifying Qi and Activating Blood on the hearts of myocardial infarction rats.
Objective:To study the stimulating angiogenesis effect of the Chinese medicine of Tonifying Qi and Activating Blood of Radix Ginseng and Radix Notoginseng formula on experimental myocardial infarction rats. Methods:A total of 100 Wistar rats were divided into normal control group, sham-operated group, untreated group, metoprolol (Betaloc) group, high-and low-dose Radix Ginseng and Radix Notoginseng formula groups. Model of myocardial ischemia was induced in the untreated group, the Betaloc group, the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups by left anterior descending coronary artery ligation. After 12-day treatment, morphological changes of Myocardial cells were observed, serum VEGF volum was detected,microvessel density (MVD) in ischemic myocardium was detected by immunohistochemical method.Result:Radix Ginseng and Radix Notoginseng formula could reduce the myocardial cell degeneration and inflammatory cells,increase blood vessel density and serum VEGF Concentration. Conclusions:Radix Ginseng and Radix Notoginseng formula could protect ischemic myocardium, and had the roles of stimulating angiogenesis in ischemic myocardium rats after acute myocardial infarction and increasing the microvessel density in ischemic myocardium.
The 2nd Experiment:Effects of the Chinese medicine of Tonifying Qi and Activating Blood on the genes expression of vascular endothelial growth factor receptor-2 and hypoxia-inducible factor-la of ischemic myocardium of rats.
Objective:To investigate the effects of the Chinese medicine of Tonifying Qi and Activating Blood of Radix Ginseng and Radix Notoginseng formula on expressions of vascular endothelial growth factor receptor-2 (VEGFR-2) and hypoxia-inducible factor-la (HIF-la) in ischemic myocardium in rats with acute myocardial infarction. Methods:The methods of modeling and treating were same to the 1st experiment. After the administration, expressions of VEGFR-2 and HIF-1αproteins were detected by Western blotting, and expressions of VEGFR-2 and HIF-1αmRNAs were detected by real-time fluorescent quantitative polymerase chain reaction. Results:VEGFR-2 and HIF-la protein and mRNA expressions in the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups and Betaloc were higher than those in the untreated group (P<0.05). There was a significant difference between the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups (P<0.05). VEGFR-2 and HIF-1αprotein and mRNA expressions in Betaloc group were higher than the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups(P<0.01). Conclusion:Radix Ginseng and Radix Notoginseng formula can up-regulate the protein and mRNA expressions of VEGFR-2 and HIF-la to improve myocardial ischemia so as to promote the development of collateral circulation in dose-dependent manner.
The 3rd Experiment:Effects of the Chinese medicine of Tonifying Qi and Activating Blood on the downstream Ras signal transduction pathway
Objective:To investigate the effects of the Chinese medicine of Tonifying Qi and Activating Blood of Radix Ginseng and Radix Notoginseng formula on the downstream Ras signal transduction pathway and probe the the signal transduction pathway that the Chinese medicine of Tonifying Qi and Activating Blood promoted angiogenesis. Methods:The methods of modeling and treating were same to the 1st experiment. After the administration, expressions of Ras、c-Raf-1、ERK1/2 and p-ERK1/2 proteins were detected by Western blotting, and expressions of Ras、c-Raf-1、ERK1 and ERK2 mRNAs were detected by real-time fluorescent quantitative polymerase chain reaction. Results:ERK1/2 protein expression was not significantly different in different groups.Ras、c-Raf-1、p-ERK1/2 proteins and Ras、c-Raf-1、ERK1/2 mRNAs expressions in the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups and Betaloc were higher than those in the untreated group (P<0.05). Conclusion:Radix Ginseng and Radix Notoginseng formula could up-regulate the protein expressions of Ras、c-Raf-1、p-ERK1/2and Ras、c-Raf-1、ERK1/2mRNA. It suggested Radix Ginseng and Radix Notoginseng formula possibly promote angiogenesis through Ras signal transduction pathway.
2. System evaluation of clinical literature the Chinese patent medicine of Tonifying Qi and Activating Blood for Unstable Angina Pectoris:a systematic review
Objective:To systematically analyze the effect of the Chinese patent medicine of Tonifying Qi and Activating Blood on unstable angina pectoris. Methods:①Search items were [Title:unstable angina pectoris] AND [All field:(Chinese medicine) OR (Chinese herb) OR (Integrated Traditional and Western Medicine)] AND [All field:(Tonifying Qi) OR (Activating Blood)], the search was applied to the CBM database (1994.1～2009.12).②Literature bolting was performed by 2 reviewers independently according to the standard of in and out, different opinions should be solved through negotiation.③The relation data of literature were extracted and evaluated.④A meta analysis was performed based on qualified literatures. Result:①170 literatures were found out.②Through twice blotting, there were 17 clinical study literatures that meeted the evaluate procedure.③17 literatures came into meta analysis procedures, the total number of cases were only 1644 cases.④The Chinese patent medicine of Tonifying Qi and Activating Blood concluded yu xin tong capsules, tong xin luo capsules, compound dan sen drop(tablet),shu xin yi mai capsules, bu chang wen xin granules,huo xue tong mai capsules,xue fu zhu yu capsules. Meta analysis showed that compared with the single conventional western medicine, additional use of Chinese patent medicine of Tonifying Qi and Activating Blood could significantly improve the symptoms of angina, the electrocardiogram, reduce the using amount of nitroglycerin and decrease plasma endothelin (ET), plasma a-granule membrane protein (GMP-140) which were close to the stability of atherosclerotic plaque.Conclusion:Meta analysis shows that Chinese patent medicine of Tonifying Qi and Activating Blood has some benefits in improving the symptoms of unstable angina, electrocardiogram and decreasing the using amount of nitroglycerin,ET and GMP-140. Due to lower quality of studies, the further study is need.
3. Literature review
123 literatures were read, collected and summarized, and progress on studies of the relationship among VEGF、CD105 and angiogenesis was explored and reviewed.A preliminary summary was conducted on literatures about Chinese medicine of Tonifying Qi and Activating Blood stimulating angiogenesis of coronary heart disease. We put forward that clinical studies combined with researches in Vitro and Vivo be conducted through many ways, many links to explore the role and signal transduction mechanisms through which chinese medicine stimulates angiogenesis of myocardial ischemia of coronary heart disease.
The research choosed the Ras protein signaling pathway as the main line, and observed the intervention of Radix Ginseng and Radix Notoginseng formula on angiogenesis in Ras signal transduction system in rats and its mechanism.It is a original research on the field of Chinese medicine's prevention and treatment of coronary heart disease.Borrowing CD105 method of detection of tumor micro vessel density, the research adopted CD105 to detect micro vessel density of myocardial ischemia.It is a innovative application of the examination index.
本论文分为三部分：基础研究、临床文献系统评价和文献综述。
一、基础研究包括以下三部分：
实验一：益气活血中药对大鼠缺血心肌的促血管生成作用
目的：观察益气活血中药人参三七组方促进大鼠缺血心肌血管新生的作用。方法：100只Wistar大鼠随机分为空白组、假手术组、模型组、倍他乐克组和大、小剂量人参三七组方组。采用冠状动脉结扎法建立大鼠急性心梗模型,并于造模后予相应药物治疗12 d。观察各组心肌细胞形态学改变,检测血清血管内皮细胞生长因子(VEGF)的表达；采用Ⅷ因子及CD105抗体检测微血管密度。结果：人参三七组方能够减轻心肌细胞变性,减少炎症细胞,增加微血管密度,提高血清VEGF的浓度。结论：人参三七组方能够保护缺血心肌细胞,具有良好促进急性心梗后大鼠缺血心肌的微血管新生,增加缺血心肌微血管密度的作用。
实验二：益气活血中药对大鼠缺血心肌VEGFR-2和HIF-1α表达的影响
目的：探讨益气活血中药人参三七组方对AMI大鼠缺血心肌VEGFR-2和HIF-1α表达的影响。方法：造模及处理方法同实验一,给药结束后,蛋白免疫印迹法检测缺血心肌的VEGFR-2和HIF-1α的蛋白表达,实时聚合酶链式反应法检测缺血心肌VEGFR-2、HIF-1αmRNA表达。结果：大、小剂量人参三七组方组及倍他乐克组VEGFR-2、HIF-1α蛋白和mRNA表达均显著高于模型组(P＜0.05)；大、小剂量组之间比较,差异亦有统计学意义。倍他乐克组VEGFR-2、HIF-1α蛋白和mRNA高于大、小剂量人参三七组方组(P<0.01)。结论：人参三七组方能够促进缺血心肌VEGFR-2、HIF-1α表达,从而改善心肌缺血,促进侧支循环的形成,具有一定剂量依赖性。
实验三：益气活血中药对Ras下游信号转导通路的影响
目的：观察益气活血中药人参三七组方对Ras信号通路的影响,探讨益气活血中药促进血管新生的信号转导途径。方法：造模及处理方法同实验一,给药结束后,蛋白免疫印迹法检测缺血心肌中Ras.c-Raf-1.ERK1／2及p-ERK1／2的蛋白表达,实时聚合酶链式反应法检测缺血心肌Ras. c-Raf-1、ERK1、ERK2 mRNA表达。结果：各组ERK1／2蛋白表达无显著性差异,大、小剂量人参三七组方组及倍他乐克组Ras.c-Raf-1、p-ERK1／2蛋白和Ras.c-Raf-1、ERK1／2mRNA表达均显著高于模型组(P＜0.05)。结论：人参三七组方能够促进缺血心肌Ras信号通路上的Ras.c-Raf-1及ERK1／2表达,说明人参三七组方可能通过Ras信号通路来促进血管新生。
二、临床文献系统评价：对1994年-2009年在科技期刊上公开发表的益气活血中成药治疗不稳定心绞痛的临床文献进行系统评价。
目的：对益气活血中成药治疗不稳定心绞痛临床研究进行系统评价。方法：①以中文标题：不稳定性心绞痛and(全部检索条目：中医or中药or中西医结合)and(全部检索条目：益气or活血)的检索式检索中国生物医学文献光盘数据库,年限为1994年1月至2009年12月。②由2位研究者按照文献纳入、排除标准独立进行文献筛选,意见不同者通过讨论解决。③获取文献的相关研究特征资料,并加以评价。④对合格的随机对照试验,进行定量的Meta分析。结果：①共检索到170个文献。②经两次筛选,剔除不符合要求以及重复报道的文献,最终共有17篇文献入选评价。③对17篇文献进行Meta分析,总病例数1644例。④益气活血中成药包括愈心痛胶囊、通心络胶囊、复方丹参滴丸(片)、舒心益脉胶囊、步长稳心颗粒、活血通脉胶囊、血府逐瘀胶囊。Meta分析显示,加用益气活血中成药干预对不稳定心绞痛患者心绞痛症状和心电图的改善较单纯西医基础治疗明显提高,能减少硝酸甘油的用量,显著降低血浆内皮素(ET)、血浆内α-颗粒膜蛋白(GMP-140)等与动脉粥样硬化斑块稳定相关指标。结论：益气活血中成药干预不稳定心绞痛在改善心绞痛的症状、心电图表现,减少硝酸甘油的用量以及降低ET、GMP-140方面有一定的疗效。但由于纳入研究的质量不高,还有待进一步研究。
三、文献综述部分通过对123篇文献的梳理和总结,探讨和综述了VEGF、CD105与血管新生的关系及其研究进展,并对益气活血法促冠心病血管新生的研究文献进行了初步总结,提出今后应临床研究与体内外实验研究相结合,从多途径、多环节探讨中药促进冠心病缺血心肌血管新生的作用及信号转导机制。
本研究以Ras蛋白信号通路为主线,观察人参、三七组方对血管生成过程中Ras信号转导系统的干预作用及其机制,属于中医药防治冠心病研究领域的原创性研究工作；借鉴CD105检测肿瘤微血管密度的方法,采用CD105检测缺血心肌的微血管密度,是检测指标的创新应用。
Therapeutic angiogenesis in ischemic diseases has become a hot topic. The Chinese medicine of Tonifying Qi and Activating Blood has a long history and certain efficacy in treating coronary heart disease(CHD). It can improve myocardial ischemic and angiogenesis of myocardial ischemia, and it has been confirmed by a lot of clinical and experimental studies, suggesting that promoting angiogenesis may be one of important mechanisms of Chinese medicine in the treatment of CHD.This study is to probe the molecular mechanism that the Chinese medicine of Tonifying Qi and Activating Blood to promote angiogenesis in myocardial ischemia rats,to reveal the role of intervention in angiogenesis and molecular targets and provide experimental evidence for the prevention and treatment of ischemic disease.
The research includes three parts:experimental research, systematic review and literature review.
1. Experimental research This part includes 3 experiments:
The 1st experiment:Stimulating angiogenesis effect of the Chinese medicine of Tonifying Qi and Activating Blood on the hearts of myocardial infarction rats.
Objective:To study the stimulating angiogenesis effect of the Chinese medicine of Tonifying Qi and Activating Blood of Radix Ginseng and Radix Notoginseng formula on experimental myocardial infarction rats. Methods:A total of 100 Wistar rats were divided into normal control group, sham-operated group, untreated group, metoprolol (Betaloc) group, high-and low-dose Radix Ginseng and Radix Notoginseng formula groups. Model of myocardial ischemia was induced in the untreated group, the Betaloc group, the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups by left anterior descending coronary artery ligation. After 12-day treatment, morphological changes of Myocardial cells were observed, serum VEGF volum was detected,microvessel density (MVD) in ischemic myocardium was detected by immunohistochemical method.Result:Radix Ginseng and Radix Notoginseng formula could reduce the myocardial cell degeneration and inflammatory cells,increase blood vessel density and serum VEGF Concentration. Conclusions:Radix Ginseng and Radix Notoginseng formula could protect ischemic myocardium, and had the roles of stimulating angiogenesis in ischemic myocardium rats after acute myocardial infarction and increasing the microvessel density in ischemic myocardium.
The 2nd Experiment:Effects of the Chinese medicine of Tonifying Qi and Activating Blood on the genes expression of vascular endothelial growth factor receptor-2 and hypoxia-inducible factor-la of ischemic myocardium of rats.
Objective:To investigate the effects of the Chinese medicine of Tonifying Qi and Activating Blood of Radix Ginseng and Radix Notoginseng formula on expressions of vascular endothelial growth factor receptor-2 (VEGFR-2) and hypoxia-inducible factor-la (HIF-la) in ischemic myocardium in rats with acute myocardial infarction. Methods:The methods of modeling and treating were same to the 1st experiment. After the administration, expressions of VEGFR-2 and HIF-1αproteins were detected by Western blotting, and expressions of VEGFR-2 and HIF-1αmRNAs were detected by real-time fluorescent quantitative polymerase chain reaction. Results:VEGFR-2 and HIF-la protein and mRNA expressions in the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups and Betaloc were higher than those in the untreated group (P<0.05). There was a significant difference between the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups (P<0.05). VEGFR-2 and HIF-1αprotein and mRNA expressions in Betaloc group were higher than the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups(P<0.01). Conclusion:Radix Ginseng and Radix Notoginseng formula can up-regulate the protein and mRNA expressions of VEGFR-2 and HIF-la to improve myocardial ischemia so as to promote the development of collateral circulation in dose-dependent manner.
The 3rd Experiment:Effects of the Chinese medicine of Tonifying Qi and Activating Blood on the downstream Ras signal transduction pathway
Objective:To investigate the effects of the Chinese medicine of Tonifying Qi and Activating Blood of Radix Ginseng and Radix Notoginseng formula on the downstream Ras signal transduction pathway and probe the the signal transduction pathway that the Chinese medicine of Tonifying Qi and Activating Blood promoted angiogenesis. Methods:The methods of modeling and treating were same to the 1st experiment. After the administration, expressions of Ras、c-Raf-1、ERK1/2 and p-ERK1/2 proteins were detected by Western blotting, and expressions of Ras、c-Raf-1、ERK1 and ERK2 mRNAs were detected by real-time fluorescent quantitative polymerase chain reaction. Results:ERK1/2 protein expression was not significantly different in different groups.Ras、c-Raf-1、p-ERK1/2 proteins and Ras、c-Raf-1、ERK1/2 mRNAs expressions in the high-and low-dose Radix Ginseng and Radix Notoginseng formula groups and Betaloc were higher than those in the untreated group (P<0.05). Conclusion:Radix Ginseng and Radix Notoginseng formula could up-regulate the protein expressions of Ras、c-Raf-1、p-ERK1/2and Ras、c-Raf-1、ERK1/2mRNA. It suggested Radix Ginseng and Radix Notoginseng formula possibly promote angiogenesis through Ras signal transduction pathway.
2. System evaluation of clinical literature the Chinese patent medicine of Tonifying Qi and Activating Blood for Unstable Angina Pectoris:a systematic review
Objective:To systematically analyze the effect of the Chinese patent medicine of Tonifying Qi and Activating Blood on unstable angina pectoris. Methods:①Search items were [Title:unstable angina pectoris] AND [All field:(Chinese medicine) OR (Chinese herb) OR (Integrated Traditional and Western Medicine)] AND [All field:(Tonifying Qi) OR (Activating Blood)], the search was applied to the CBM database (1994.1～2009.12).②Literature bolting was performed by 2 reviewers independently according to the standard of in and out, different opinions should be solved through negotiation.③The relation data of literature were extracted and evaluated.④A meta analysis was performed based on qualified literatures. Result:①170 literatures were found out.②Through twice blotting, there were 17 clinical study literatures that meeted the evaluate procedure.③17 literatures came into meta analysis procedures, the total number of cases were only 1644 cases.④The Chinese patent medicine of Tonifying Qi and Activating Blood concluded yu xin tong capsules, tong xin luo capsules, compound dan sen drop(tablet),shu xin yi mai capsules, bu chang wen xin granules,huo xue tong mai capsules,xue fu zhu yu capsules. Meta analysis showed that compared with the single conventional western medicine, additional use of Chinese patent medicine of Tonifying Qi and Activating Blood could significantly improve the symptoms of angina, the electrocardiogram, reduce the using amount of nitroglycerin and decrease plasma endothelin (ET), plasma a-granule membrane protein (GMP-140) which were close to the stability of atherosclerotic plaque.Conclusion:Meta analysis shows that Chinese patent medicine of Tonifying Qi and Activating Blood has some benefits in improving the symptoms of unstable angina, electrocardiogram and decreasing the using amount of nitroglycerin,ET and GMP-140. Due to lower quality of studies, the further study is need.
3. Literature review
123 literatures were read, collected and summarized, and progress on studies of the relationship among VEGF、CD105 and angiogenesis was explored and reviewed.A preliminary summary was conducted on literatures about Chinese medicine of Tonifying Qi and Activating Blood stimulating angiogenesis of coronary heart disease. We put forward that clinical studies combined with researches in Vitro and Vivo be conducted through many ways, many links to explore the role and signal transduction mechanisms through which chinese medicine stimulates angiogenesis of myocardial ischemia of coronary heart disease.
The research choosed the Ras protein signaling pathway as the main line, and observed the intervention of Radix Ginseng and Radix Notoginseng formula on angiogenesis in Ras signal transduction system in rats and its mechanism.It is a original research on the field of Chinese medicine's prevention and treatment of coronary heart disease.Borrowing CD105 method of detection of tumor micro vessel density, the research adopted CD105 to detect micro vessel density of myocardial ischemia.It is a innovative application of the examination index.
引文
1. Ware JA,SimonsM.Angiogenesis in ischemic heart disease[J].Nature Med,1997,3(2):158-164
2. Syed IS,Sanborn TA,Rosengart TK.Therapeutic angiogenesis:abiologic bypass.Cardiology,2004,101:131-143
3.刘郁,刘连新.人参功效再认识.时珍国医国药,2006,17(2)：289
4.王培利,雷燕,林燕林,陈可冀.当归补血汤含药血清对培养内皮细胞生长因子受体表达的影响[J].中西医结合心脑血管病杂志,2006,4(3)：209-212.
5.雷燕,王培利,林燕林,陈可冀.当归补血汤煎剂对实验性心肌梗死衰老大鼠缺血心肌的促血管生成作用[J].中国中医基础医学杂志,2005,(12)：892-894.
6.田伟,雷燕,王硕仁.人参、三七组方对Ras相关信号蛋白的影响[J].中国中西医结合杂志,2009,29(9)：802-805.
7.刘德恒,徐真真,郭伟聪.冠心病心绞痛395例中医证型特点探讨[J].中医杂志,1995,36(10)：617-618.
8.李贻奎,宁可永,梁嵘,李连达.大鼠冠状动脉结扎心肌缺血模型方法的改进[J].中国新药杂志,2005,14(4)：427-428.
9.徐叔云,卞如镰,陈修.药理学实验方法(M).第3版.北京：人民卫生出版社,2005,1052-1053
10. Fonsatti E,Jekunen AP,Kairemo KJ,et al.Endoglin is a suitable target for efficient imaging of solid tumors:in vivo evidence in a canine mammary carcinoma model.Clinical cancer research,2000,6(5):2037-2043
11. Weidner N.Intratumor microvessel density as a rognostic factor in cancer.Am J Pathol,1995,147(1):9-19
12. Ng YS,Krilleke D,Shima DT.VEGF function in vascular pathogenesis.Experimental Cell Research,2006,312:527-537.
13. Pradeep CR,Sunila ES,Kuttan G. Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies.Inter Cancer Ther,2005,4(4):315-321
14.张晓东,徐传达等VEGF在实验性心肌梗赛中促血管生成的实验研究.中国临床解剖学杂志,2001,19(2)：167-169
15.刘清霞,张宏颖.急性心肌梗塞早期使用美托洛尔预防心率失常的临床观察.河南医学研究,2009,2(18)：122-123
16.佘强,陈运贞.β受体阻滞剂促大鼠缺血心肌血管新生的实验研究[J].重庆医科大学学报,2001(2)：146-150
17.张蕊,刘兴德.美托洛尔对大鼠缺血心肌血管新生及血管内皮生长因子表达的影响.贵阳医学院学报,2008,33(1)：23-25
18. Brown MD,Davies MK,Hudlicka O.The effect of long-term bradycardia on heart microvascular supply and performance.Cell Mol Biol Res,1994,40(2):137-142
19. Zheng W,Bown MD,Brock TA,et al.Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor.CirRes,1999,85(2):192-198
20. Lei L,Zhou RF,Zheng W,et al.Bradycardia induces angiogenesis,increases coronary reserve,and preserves function of the postinfarcted heart.Circulation,2004,(110):796-802
21.郭洁文,杨敏,朱剑光等.三七总皂甙对心血管作用的药理研究新进展.现代食品与药品杂志,2007,17(2)：1-3
22. Wikstrom P,Lissbrant IF,Stattin P, et al. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate,2002,51(4):268-275
1. Gille H,Kowalski J,Li B,et al.Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2).A reassessment using novel receptor-specific vascular endothelial growth factor mutants.J Biol Chem, 2001,276(5):3222-3230.
2. Gerber HP,McMurtrey A,Kowalski J,et al.Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway.Requirement for Flk-1/KDR activation. J Biol Chem,1998,273(46):30336-30343.
3. Zeng H,Sanyal S,Mukhopadhyay D.Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively.J Biol Chem,2001,276(35):32714-32719.
4. Muklerjee S,Tessema M,Wandinger—Ness A.Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function[J].Cire Res,2006m98(6):743-756
5. LeeSH,WolfPL,EseuderoR,et al.Early expression of angiogenesis factoes in acute myocardial ischemia and infarction[J].N Engl J Med,2000,342(2):1487-1493
6. Liu Lx,Lu H. Stabilization of vascular endothelial growth factor mRNA by hypoxia-induciblefactorl[J].BiochemBiophysResCommum,2002,291(4):908-914
7. Asahara T,Murohara T,Sullivan A,et al.Isolation of putative progenitor endothelial cells for angiogenesis. Science,1997,275(5302):964-967.
8. Schaper W,Ito WD.Molecular mechanisms of coronary collateral vessel growth. Circ Res,1996,79(5):911-919.
9. Ng YS,Krilleke D,Shima DT.VEGF function in vascular pathogenesis.Exp Cell Res,2006,312(5):527-537.
10. Neufeld G, Kessler O, Herzog Y.The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv Exp Med Biol,2002,515:81-90.
11. Mukherjee S,Tessema M,Wandinger-Ness A.Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res,2006,98(6):743-756.
12. Lee SH,Wolf PL,Escudero R,et al.Early expression of angiogenesis factors in acute myocardial ischemia and infarction.N Engl J Med,2000,342(9):626-633.
13.倪永兵.低氧诱导因子1和血管内皮生长因子与血管新生.国外医学·生理、病理科学与临床分册,2002,22(3)：266-269.
14.王忠秀,杨林花HIF-1、VEGF与缺血性脑血管病.血栓与止血学,2007,13(4)：189-192.
1. Bokemeyer D,Sorokin A,Dunn MJ.Multiple intracellular MAP kinase signaling cascades[J].Kidney Int,1996,49(5):1187-1198
2. Reddy KB,Nabha SM,Atanaskova N,et al.Role of MAP kinase in tumor progression and invasion,2003,22(4):395-403
3. Phillips RA,Hunter JL,Eccleston JF,et al.The mechanism of Ras GTPase activation by neurofibromin,2003,42(13):3956-65.
4. Asha H,Nagy I,Kovacs G,etal.Analysis of Ras-induced overproliferation in Drosophila hemocytes,Genetics,2003,163:203-215
5. Bivona TQPerez De,Castro I,et al.Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1.Nature,2003,424:694
6. McKenna WG,Muschel RJ,Gupta AK,et al.The RAS signal transduction pathway and its role in radiation sensitivity.Oncogene,2003,22(37):5866.
7. Kolch W,Biochem J.Meaningful relationships:the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.2000,351 (2):289-305.
8. Hilger RA,Scheulen ME,Strumberg D.The Ras-Raf-MEK-ERK pathway in the treatment of cancer.Oncology,2002,25:511-518
9. Davis RJ.Signal transduction by the JNK group of MAP kinases.Cell,2000,103:239-252
10.刘秉文,陈俊杰.医学分子生物学.北京：中国协和医科大学出版社,2005,131-197
11. Mavria G,Vercoulen Y,Yeo M,et al.ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis.Cancer Cell,2006,9(1):33-44.
12. David M,Petricoin E,Benjamin C,et al.Requirement for MAP kinase(ERK2) activity in interferon-x and interferon-x-stimulated gene expression through STAT proteins. Science,1995,269:1721-1723.
13. WidmannC,Gibosn S,Jarpe MB,et al.Mitrogen-activated protein kinase conservation of a three-kinase module from yeast to human.Physiol Rev,1999,79(1):143-180
1. 高润霖,吴宁,胡大一.心血管病治疗指南和建议.北京：人民军医出版社,2005：1
2. 陈可冀,雷燕.加强不稳定性心绞痛的防治研究[J].中国中西医结合杂志,1996,16(10)：579
3. 雷燕,陈可冀,柯元南,等.愈心痛胶囊治疗不稳定性心绞痛临床研究[J].中国中西医结合杂志,1996,16(10)：580-583
4. 李松林,罗纯.通心络胶囊治疗不稳定性心绞痛疗效分析[J].医学文选,2000,19(2)：208
5. 金露.复方丹参滴丸对冠心病不稳定性心绞痛患者血小板活化功能的影响[J].中国中西医结合杂志,2000,20(6)：415-417
6. 王听.复方丹参滴丸治疗不稳定性心绞痛疗效观察[J].解放军药学学报,2001,17(2)：78-80
7. 李如兰.通心络治疗不稳定性心绞痛34例[J].中国中医急症,2001,10(2)：107-108
8. 杨丁友,段学忠,周次清.舒心益脉胶囊对冠心病不稳定性心绞痛患者血小板活化功能的影响[J].中国实验方剂学杂志,2001,7(4)：50-51
9.平玉兰.复方丹参含片治疗不稳定性心绞痛76例[J].河南医药信息,2002,10(6)：6-9
10.苏玉国.中西医结合治疗不稳定性心绞痛疗效观察[J].山西中医,2004,20(4)：27-28
11.李亚秋.步长稳心颗粒联合常规用药治疗不稳定性心绞痛[J].中国实用医药,2008,3(5)：62-63
12.孙丽,张慧恩,郭晓玲,等.步长稳心颗粒治疗不稳定性心绞痛的疗效观察[J].中国现代药物应用,2008,2(17)：53
13.郭志忠,郭红星,郭显玲.中西医结合治疗不稳定性心绞痛90例疗效观察[J].中国中西医结合民间疗法,2008,2：18
14.孙朝阳,侯玉娟,苏旻.通心络胶囊联合低分子肝素钠治疗不稳定性心绞痛50
例[J].方药应用中国民间疗法,2008,11：33-34
15.张艳霞,陈桂玲.通心络对不稳定性心绞痛血浆内皮素的影响及疗效观察[J].中国中医药现代远程教育,2008,6(5)：441-442
16.王萍.中西医结合治疗老年不稳定性心绞痛临床观察[J].湖北中医杂志,2009,31(2)：32-33
17.马建平.通心络胶囊治疗不稳定性心绞痛28例[J].方药应用中国民间疗法,2009,17(9)：39
18.郑国玲,王盛华.血府逐瘀胶囊治疗不稳定性心绞痛的临床疗效观察及机制探讨[J],2009,29(1)：65-68
19.张静,李国武.通心络胶囊治疗不稳定性心绞痛的疗效观察[J].西部医学,2009,21(8)：1352-1353
20.邢雁伟,王阶,衷敬柏,等.采用聚类分析和对应相关方法研究1069例冠心病心绞痛证候应证组合规律[J].中华中医药杂志,2007,22(11)：747-750
21. Lush TF, Wenzel RR. Endothelial and endothelin antagonisis pharmacology and clinical implication[J].Agents Actions Suppl,1995,45:237
22.张静,张菲斐.心绞痛患者血小板α颗粒膜蛋白及D-二聚体的变化[J].中华内科杂志,1999,38(8)：527-529
23.吴国新,阮长耿.血小板颗粒膜蛋白研究进展[J].中华血液学杂志,1994,15(3)：162-164
1.胡大一,马长生.心脏病学实践2008-规范化治疗[M].北京：人民卫生出版社,2009,3
2. Engerman RL,Pfaffenbach D,Davis MD.Cell turnover of capillaries.Lab Invest,1967,17(6):738-743.
3. Judah Folkman.Angiogenesis in cancer vascular rheumatoid and other disease. Nature Medicine,1995,1:27-30
4. Folkman J.Angiogenesis[J].Annu Rev Med,2006(57):1-18
5. Hanahand,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell,1996,86(3):353-364
6. SchaperW,ItoWD.Molecular mechanisms of cornonary collateral vessel growth[J].Cire Res,1996,79(5):911-919
7. Neufeld QKessler O,Herzog Y.The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF.Adv Exp Med Biol,2002,515:81-90
8. Thurston G,Rudge JS,Ioffe E,et al.Nat Med,2000,6(4):460-463
9. Kobayashi H,Lin PC.Angiopoietin/Tie2 signaling tumor angiogenesis and inflammatory diseases.Front Biosci,2005,10:666-74
10. Plank MJ,Sleeman BD,Jones PF.The Role of the Angiopoietins in tumour angiogenesis.Growth Factors,2004,22:1-11
11. Metheny-barlow LJ,LI LY.The enigmatic role of the angiopoietins in tumour
angiogenesis.Cell Res,2003,13:309-317
12. Fan TPD,Jaggar R,Bicknell R.Controlling the vasculature:Angiogenesis anti-angiogenesis and vascular targeting of gene therapy.Trends Pharmacol Sci,1995,16(2):57-66
13. Itch T,Tanioka M,Yoshida H,et al.Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.Cancer Res,1998,58(5):1048-051
14. Ehringer WD, Wang OL, Haq A, Miller FN. Bradykinin and a-thromb increase human umbilical vein endothelial macromolecular permeability by different mechanisms.Inflammation,2000,24(2):175-193
15. Bellon QMartiny L,Robinet A.Matrix metalloproteinases and matrikinesin angiogenesis.Crit Rev Oncel Hematol,2004,49(3):203-220
16. Harada K,Friedman M,Lopez JJ,etal.Vascular endothelial growth administration in chronic myocardial ischemia[J].Am J Physiol,1996,270(5Pt2):H1719
17. Schaper W,Buschmann I.Arteriogenesis,the good and bad of it.Cardiovasc Res,1999,43(4):835-837
18. Plate KH,Breior QWeich HA,et al.angiogenesis:Molecule and mode.Nature,1992,359:845-848
19. Ausprunk DH,Folkman J.Migration and proliferation of endothelial cells in performed and newly formed blood vessels during tumor angiogenesis.Microvasc Res,1977,14:53.
21. Folktnan J.Haudenschild, C.Natute,1980,288:551-556.
23. D'Amore PA.Capillary Growth:a two cell syssterm.Semin Cancer Biol,1992,3:49.
24. Plate KH,Breior G,Weich HA,et al.angiogenesis:Molecule and mode.Nature,1992,359:845-848
25.刘启功,王琳,陆再英,等.葛根素对心肌梗塞犬冠脉侧枝循环的影响.中国中药
杂志,1999,24(5)：304-306.
26.关国跃,石耀辉,唐丕玉.葛根素改善缺血性心肌血流灌注的探讨.心血管康复医学杂志,2001,10(1)：71-72.
27.刘启功,王琳,陆再英,等.丹参注射液对犬缺血心肌更新供血的影响.中国医院药学杂志,1999,19(11)：653-655.
28.刘启功,孙玉梅,程燕子等.丹参限制犬心肌梗死范围及其机制的研究.中国现代医学杂志,2005,15(15)：2257-2259
29.吴旭,晋军,梁自文,等.蜕皮甾酮对冠状动脉闭塞致大鼠心肌梗死的有益作用及机制.中草药,2001,32(8)：721-723.
30.李朝武,刘新泳,张蕊等.川芎醇对血管内皮细胞增殖与损伤保护作用的研究.山东大学学报(医学版).2003,41(4)：402-407.
31.刘新泳,赵全芹,李朝武等.川芎咔啉碱的合成及其对血管内皮细胞损伤的保护作用.山东大学学报(医学版),2003,41(5)：485-487
32..李剑,范维琥,敖红,等.中药红景天对大鼠缺血心肌Flt1、KDR及Tie2表达的影响.中国中西医结合杂志,2005,25(5)：445-448
33.李剑,范维琥,罗心平,等.预灌红景天对心梗大鼠心功能Flk-1mRNA表达的影响.复旦学报(医学版),2006,33(3)：384-387
34.雷燕,王军辉,陈可冀.黄芪、当归配伍后促鸡胚绒毛尿囊膜血管生成的药效比较研究.中国中药杂志,2003,28(9)：876-878.
35.雷燕,高倩,李悦山,等.黄芪、当归及其组方促血管内皮细胞增殖作用的研究.中国中西医结合杂志,2003,23(10)：753-756.
36.雷燕,王培利,林燕林,等.当归补血汤煎剂对实验性心肌梗死衰老大鼠缺血心肌的促血管生成作用.中国中医基础医学杂志,2005,11(12)：892-894.
37.王培利,雷燕,林燕林等.当归补血汤含药血清对培养内皮细胞生长因子受体表达的影响.中西医结合心脑血管病杂志,2006,4(3)：209-212.
38.孟君,冯君.心脉通胶囊对急性心肌梗死病人血管内皮生长因子表达的影响.广州中医药大学学报,2002,19(2)：88-89
39.汪姗姗,李勇,范维琥,等.麝香保心丸对实验性心肌梗塞大鼠心脏的促血管生成作用.中成药,2002,24(6)：446-449.
40.汪姗姗,李勇,范维琥等.麝香保心丸对鸡胚绒毛尿囊膜及培养的血管内皮细胞的促血管生成作用.中国中西医结合杂志.2003,23(2)：128-131
41.杨祖福,胡婉英,秦志强,等.双龙丸对大鼠实验性心肌梗死血管新生的影响与分子学机制.中国康复理论与实践,2003,9(5)：293-295
42.王文健,傅晓东,陈伟华等.通心络促血管新生作用的实验研究.疑难病杂志,2003,2(1)：2-4
43.韩丽华,王振涛,索红亮,等.益气活血方促心梗后大鼠缺血心肌血管新生的实验研究.河南中医,2005,25(11)：21-23
44.张宗棨,邢之华,唐涛,等保心汤对心肌梗死PTCA患者血清VEGF的影响.北京中医药大学学报,2006,29(4)：277-280
45.尹慧秋,张继东,林海青,等舒脉胶囊对大鼠缺血心肌促血管新生的影响.中国中西医结合杂志,2007,27(11)：1020-1022
46.冯玲,曹洪欣,胡元会,等.温阳益心方对大鼠心肌梗死模型心肌梗死面积及梗死边缘区血管密度的影响.中西医结合心脑血管杂志,2009,7(2)：165-166
1. Pradeep CR, Sunila ES, Kuttan G.Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.Integrative cancer therapies,2005,4 (4):315-321
2. Senger DR, Galli SJ, Dvorak AM.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.Science,1983,219:983-985
3. Ferrara N,Henzel WJ.Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.Biochem Biophys Res Commun,1989,161(2):851-858.
4. Ueda M,Terai Y,Kumagai K.Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells.Gynecol Oncol,2001,82(1):162-166
5. Brown LF,Detmar M,Claffey K,et al. Vasclular permeability factor/vascular endothelial growth factor:a multifunctional angiogenic cytokine.Hum Genet.1997,79:233
6. Akagi K,Ikeda Y,Miyazaki M,et al.Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues.Br J Cancer,2000,83(7):887-891.
7.陈治,杜钰.血管内皮细胞特异性受体在肿瘤血管靶向治疗中的应用.世界华人消化杂志,2001,9(6)：702-705
8. Zeng H,Dvorak HF,Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2 mediated endothelial cell proliferation,but not migration,through phosphatidylinositol 3-kinase-dependent pathways.J Bio Chem,2001,276(29):26969-26979.
9. Soker S,Takashima S,Miao HQ,et al.Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.Cell,1998,92:735-745
10. Ferrara N,Davis-Smyth.The biology of vascular endothelial growth factor.Endocr Rev,1997,18:4-25
11. Lebherz C,Degenfeld G,Karl A,et al.Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb:effect of venous basic fibroblast growth factor retroinfusion,2003,10:257-265
12. Gerber HP,McMurtrey A,Kowalski J,et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway requirement for Flk-1/KDR action.J Biol Chem,1998,273:30336-30343
13. Gerber HP, Hillan KJ,Ryan AM,et al. VEGF is required for growth and survival in neonatal mice.Development,1999,126:1149-1159
14. de Vries C,Escobedo JA, Ueno H. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science,1992,255:989-991
15. Andrew P,Levy NS,Levy JL,et al.Regulation of vascular endothelial growth factor in cardiac myocytes.Circ Res,1995,76(5):758-766.
16. Ariadne M,john T,Anastasia T,et al. Changes in serum levels of vascular endothelial growth factor in males and females throughout life.Soc Gynecol Investing,2000,7(5):309-312
17. Duyndam MC,Hilhorst MC,Schluper HM, et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Patho,2002,160(2):537-548
18.周泉.血管内皮生长因子的生物学特性及临床研究进展[J].实用心脑肺血管病杂志,2001,9(1)：51-54.
19. Muklerjee S,Tessema M,Wandinger—Ness A.Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function[J].Cire Res,2006,98(6):743-756
20. LeeSH,WolfPL,EseuderoR,etal.Early expression of angiogenesis factoes in acute myocardial ischemia and infarction[J].N Engl J Med,2000,342(2):1487-1493
21. Rak J,Yu JL,Kiement G,et al.Oncogenes and angiogenesis:signaling three-dimensional umor growth.Investing Dermathol Symp Proc,2000,5(1):24-33
22. Strohmeyer D,Rossing C,Bauerfeind A,et al.Vascular endothelial growth factor and its correlation with angiogenesis and P53 expression in protate cancer[J]. Prostate,2000,45 (3):216-224.
23. Frank S,Hubner QBreier G,et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem,270,12607-12613
24. Brogi E,Wu T,Namiki A,et al. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression invascular smooth muscle cells,whereas hypoxia upregulates VEGF expression only. Circulation,1994,90:649-652
25. HaradaK,Friedman m,.Lopez JJ.Vascwlar endothelial growth factor admimistration in chronic myocardial ischemia.Am Journal Physnol,1996,270:1791-802
26. Sato K, Wu T, Laham RJ,et al.Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia,J Am Coll Cardiol,2001,37(2):616-623.
27. Zhou ZM.Debabrata M.Wang K Induction of angiogenesis in a canine model of chronic myocardial ischemia with intravenous infusion of Vascular Endothelial Growth Factor(VEGF) combined with ultrasound energy and echo contrast agent. J Am Coll Cardiol,2002,39(Supplement2):396
28. Rutanen J,Rissanen TT,Markkanen JE,et al.Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation, 2004,109(8):1029-1035
29. Muhlhanser J,Merrill MJ,Pili R.VEGF165 expressed by a rephication deficient recombinant adenoviras rector induces angiogenesis in vivo.Circ Res,1995, 77:1077-1086
30. Lee LY,Patel SR,Hackett NR,et al.Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial gronth factor 121.Ann Thorac Surg,2000,69:14-24
31. Kornowski R,Leon MB,Fuchs S,et al.Electromagnetic guidance for catheter-based transendocardial injection:a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models.J Am CollCardiol,2000,35:1031-1039
32. Schalch P,Rahman GF,Patejunas G,et al. Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state.J Thorac Cardiovasc Surg,2004,127:535-540
33. Suzuki K,Murtuza B,Smolenski RT.Cell transplatation for treatment of myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts.Circulation,2001,9(104):207-212
34. Xiaojin H,Agneta M B,et al.Myocardial angiogenesis after plasmid or adenoviral VEGF-A 165 gene transfer in rat myocardial infraction.Model.Cardio Res,2007,73:481
35. Douglas W,Losordo DW,Vale PR, et al.Gene therapy for myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.[J].Circulation,1998,98(12): 2800-2804.
36. Rosengart TK,Lee LY,Patel SR,et al.Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA[J].A nn Surg,1999,230(4):466-470
37..Symes JF,.Losordo DW,Vale PR,et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg,1999,68:830-836
38. Henry TD, Annex BH,McKendall GR,et al. The VIVA trial:Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation,2003,107:1359-1365
39. Losordo DW,Vale PR, Hendel RC,et al.Phase 1/2 placebo-controlled, double-blind,dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia.Circulation,2002,105:2012-2018
40. Amerian Heart Association. Amerian Heart Association's Top 10 research advances for 2001 include heart device,cell transplants and drug-eluting stents.2001 Year-end Report,2001
41. Schwarz E R,Speakman M T,Patterson M,et al.Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor(VECF)in a myocardial infarction model in the rat-angiogenesis and angioma formation.J Am Coll Cardiol,2000.35(5):1323
1. Fonsatti E,Jekunen AP,Kairemo KJ,et al.Endoglin is a suitable target for efficient imaging of solid tumors:in vivo evidence in a canine mammary carcinoma model.Clinical cancer research,2000,6(5):2037-2043
2. Quackenbush EJ,Letarte M.Identification of several cell surface proteins of non-T,non-B acute lymphoblastic leukemia by using monoclonal antibodies.J Immunol,1985,134(2):1276-1285.
3. Gougos A,Letarte M.Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line.J Immunol,1988,141(6):1925-1933.
4. Gougos A,Letarte M.Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line.J Immunol,1988,141(6):1934-1940
5.金伯泉主编.细胞和分子免疫学[M].上海世界图书出版公司,1995,2-3.
6. Haruta Y,Seon BK.Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.Proc Nati Acad Sci USA,1986,63:7898-7902
7. Fernandez-Ruiz E,St-Jacques S,Bellon T,et al.Assignment of the human endoglin gene (END) to 9q34→qter [J]. Cytogenet Cell Genet,1993,64:204.
8. Pichuantes S,Vera S,Bourdeau A,et al.Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments.Tissue Antigens,1997,50:265-276.
9. ParkerJ.M.R,Guo Dand Hodges R.S.New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data:correlation of predicted surface residues with antigenicity and x-ray-derived accessible sites. J Biochem,1986,25(19):5425-5432.
10. Yamashita H,Ichijo H,Grimsby S,et al.Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta.J Biol Chem,1994,269(3):1995-2001.
11. Fonsatti E,Del Vecchio L,Altomonte M,et al.Endoglin:An accessory component of the TGF-beta-binding receptor-complex with diagnostic,prognostic,and bioimmunotherapeutic potential in human malignancies.J Cell Physiol,2001,188(1):1-7.
12. Cheifetz S,Hernandez H,Laiho M,et al.Distinct transforming growth factor-β (TGF-β)receptor subsets as determination of cellular responsiveness to three TGF-β isforms. J BiolChem,1990,265:20533-20538.
13. Cheifetz S,Bellon T,Cales C,etal.Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells.Biol Chem,1992,267:19027-19030.
14. Guerrero-Esteo M,Sanchez-Elsner T,Letamendia A,et al.Extra cellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors Ⅰ and Ⅱ [J].J Biol Chem,2002,277 (32):29197-29209.
15. Lastres P,Letamendia A,Zhang H,et al.Endoglin modulates cellular responses to TGF-beta 1 [J].J Cell Biol,1996,133(5):1109-1121.
16. Wahl SM.Transforming Growth Factor:The Good,the Bad and the Ugly.J Exp Med,1994,180(5):1587-1590.
17. Heldin CH,Miyazono K,Ten Dijke P.TGF-beta signaling from cell membrane to nucleus through SMAD proteins [J].Nature(London),1991,390:465-471.
18. Lastres P,Letamendia A, Zhang H,et al.Endoglin modulates cellular responses to TGF-beta 1 [J].J Cell Biol,1996,133(5):1109-1121.
19. Li C,Guo B,Wilson PB,et al. Plasma levels of soluble CD 105 correlate with metastasis in patients with breast cancer. Int J Cancer,2000,89(2):122-126.
20. Li C,Hampson IN,Hampson L,et al.CD105 antagonizes the inhibitory signaling of transforming growth factor betal on human vascular endothelial cells [J].FASEB J,2000,14(1):55-64.
21. Bourdeau A,Faughnan ME,Letarte M.Endoglin-deficient Mice,a unique model to study hereditary hemorrhagic telangiectasia.Trends Cardiovasc Med,2000,10(7):279-285
22..Dickson MC,Martin JS,Cousins FM,et al.Defective haematopoiesis and vasculogenesis in transforming growth factor-1 knock out mice. Development,1995,121:1845-1854
23. Li DY,Sorensen LK,Brooke BS,et al.Defective angiogenesis in mice lacking endoglin. Science,1999,284(5419):1534-1537.
24. Bourdeau A,Dumont DJ,Letarte M,et al.A murine model of hereditary hemorrhagic telangiectasia. J ClinInvest,1999,104(10):1343-1351.
25. van den Driesche S, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia:an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis.Cardiovasc Res,2003,58(1):20-31
26. Kim YJ,Varki NM,Varki A,et al.P-selectin deficiency attenuates tumor growth and metastasis. Proc NatI Acad Sci USA,1998,95(16):9325-9330
27. Miller DW,Graulich W,Karges B,et al.Elevated expression of endoglin,a component of the TGF-beta-receptor complex,correlates with proliferation of tumor endothelial cell. Int J Cancer,1999,81(4):568-572
28. Wikstrom P,Lissbrant IF,Stattin P,et al.Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate, 2002,51(4):268-275
29. Warrington K,Hillarby MC,Li C,et al.Funtional role of CD105 in TGF-betal signalling in murine and human endothelial cells[J].Anticancer Res,2005, 25(3B)：1851-1864
30.崔松,吕树铮,陈韵岱,等.冠心病患者可溶性CD105与hs-CRP水平相关分析.心肺血管杂志,2008,27(2)：75-78
31. Bodey B,Bodey JR,Siegeal SE,et al. Over-expression of endoglin (CD105):a marker of breast carcinoma-induced neo-vascularization.Anticancer Res,1998,18(5A):3621-3628.
32. Tanaka F,Otake Y,Yanagihara K,et al. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer:comparison between CD 105 and CD34 as a marker of angiogenesis.Lung Cancer,2003,39(3):289-296
33. Saad RS,Jasnosz KM,Tung MY,et al. Endoglin (CD105) Expression in Endometrial Carcinoma.Int J Gyneocol Pathol,2003,22(3):248-253
34.李大林,李杨,李传祖等.CD 105和VEGF在大肠癌新生血管中的表达.中国普痛外科杂志,2003,12(11)：815-818
35. Pang D,Liu F,Xue YW,et al. Clinicopathologic significance of CD105 mRNA expression in human breast carcinoma[J].Zhong hua Zhong Liu Za Zhi,2005,27(1):38-40.
36. Chien CY,Su CY,Hwang CF,et al.Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx[J].Head Neck,2006,28(5):441-446
37. Kyzas PA,Agnantis NJ,Stefanou D.Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Archiv,2006,448(6):768-775
2. Syed IS,Sanborn TA,Rosengart TK.Therapeutic angiogenesis:abiologic bypass.Cardiology,2004,101:131-143
3.刘郁,刘连新.人参功效再认识.时珍国医国药,2006,17(2)：289
4.王培利,雷燕,林燕林,陈可冀.当归补血汤含药血清对培养内皮细胞生长因子受体表达的影响[J].中西医结合心脑血管病杂志,2006,4(3)：209-212.
5.雷燕,王培利,林燕林,陈可冀.当归补血汤煎剂对实验性心肌梗死衰老大鼠缺血心肌的促血管生成作用[J].中国中医基础医学杂志,2005,(12)：892-894.
6.田伟,雷燕,王硕仁.人参、三七组方对Ras相关信号蛋白的影响[J].中国中西医结合杂志,2009,29(9)：802-805.
7.刘德恒,徐真真,郭伟聪.冠心病心绞痛395例中医证型特点探讨[J].中医杂志,1995,36(10)：617-618.
8.李贻奎,宁可永,梁嵘,李连达.大鼠冠状动脉结扎心肌缺血模型方法的改进[J].中国新药杂志,2005,14(4)：427-428.
9.徐叔云,卞如镰,陈修.药理学实验方法(M).第3版.北京：人民卫生出版社,2005,1052-1053
10. Fonsatti E,Jekunen AP,Kairemo KJ,et al.Endoglin is a suitable target for efficient imaging of solid tumors:in vivo evidence in a canine mammary carcinoma model.Clinical cancer research,2000,6(5):2037-2043
11. Weidner N.Intratumor microvessel density as a rognostic factor in cancer.Am J Pathol,1995,147(1):9-19
12. Ng YS,Krilleke D,Shima DT.VEGF function in vascular pathogenesis.Experimental Cell Research,2006,312:527-537.
13. Pradeep CR,Sunila ES,Kuttan G. Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and Malignancies.Inter Cancer Ther,2005,4(4):315-321
14.张晓东,徐传达等VEGF在实验性心肌梗赛中促血管生成的实验研究.中国临床解剖学杂志,2001,19(2)：167-169
15.刘清霞,张宏颖.急性心肌梗塞早期使用美托洛尔预防心率失常的临床观察.河南医学研究,2009,2(18)：122-123
16.佘强,陈运贞.β受体阻滞剂促大鼠缺血心肌血管新生的实验研究[J].重庆医科大学学报,2001(2)：146-150
17.张蕊,刘兴德.美托洛尔对大鼠缺血心肌血管新生及血管内皮生长因子表达的影响.贵阳医学院学报,2008,33(1)：23-25
18. Brown MD,Davies MK,Hudlicka O.The effect of long-term bradycardia on heart microvascular supply and performance.Cell Mol Biol Res,1994,40(2):137-142
19. Zheng W,Bown MD,Brock TA,et al.Bradycardia-induced coronary angiogenesis is dependent on vascular endothelial growth factor.CirRes,1999,85(2):192-198
20. Lei L,Zhou RF,Zheng W,et al.Bradycardia induces angiogenesis,increases coronary reserve,and preserves function of the postinfarcted heart.Circulation,2004,(110):796-802
21.郭洁文,杨敏,朱剑光等.三七总皂甙对心血管作用的药理研究新进展.现代食品与药品杂志,2007,17(2)：1-3
22. Wikstrom P,Lissbrant IF,Stattin P, et al. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate,2002,51(4):268-275
1. Gille H,Kowalski J,Li B,et al.Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2).A reassessment using novel receptor-specific vascular endothelial growth factor mutants.J Biol Chem, 2001,276(5):3222-3230.
2. Gerber HP,McMurtrey A,Kowalski J,et al.Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway.Requirement for Flk-1/KDR activation. J Biol Chem,1998,273(46):30336-30343.
3. Zeng H,Sanyal S,Mukhopadhyay D.Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively.J Biol Chem,2001,276(35):32714-32719.
4. Muklerjee S,Tessema M,Wandinger—Ness A.Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function[J].Cire Res,2006m98(6):743-756
5. LeeSH,WolfPL,EseuderoR,et al.Early expression of angiogenesis factoes in acute myocardial ischemia and infarction[J].N Engl J Med,2000,342(2):1487-1493
6. Liu Lx,Lu H. Stabilization of vascular endothelial growth factor mRNA by hypoxia-induciblefactorl[J].BiochemBiophysResCommum,2002,291(4):908-914
7. Asahara T,Murohara T,Sullivan A,et al.Isolation of putative progenitor endothelial cells for angiogenesis. Science,1997,275(5302):964-967.
8. Schaper W,Ito WD.Molecular mechanisms of coronary collateral vessel growth. Circ Res,1996,79(5):911-919.
9. Ng YS,Krilleke D,Shima DT.VEGF function in vascular pathogenesis.Exp Cell Res,2006,312(5):527-537.
10. Neufeld G, Kessler O, Herzog Y.The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF. Adv Exp Med Biol,2002,515:81-90.
11. Mukherjee S,Tessema M,Wandinger-Ness A.Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function. Circ Res,2006,98(6):743-756.
12. Lee SH,Wolf PL,Escudero R,et al.Early expression of angiogenesis factors in acute myocardial ischemia and infarction.N Engl J Med,2000,342(9):626-633.
13.倪永兵.低氧诱导因子1和血管内皮生长因子与血管新生.国外医学·生理、病理科学与临床分册,2002,22(3)：266-269.
14.王忠秀,杨林花HIF-1、VEGF与缺血性脑血管病.血栓与止血学,2007,13(4)：189-192.
1. Bokemeyer D,Sorokin A,Dunn MJ.Multiple intracellular MAP kinase signaling cascades[J].Kidney Int,1996,49(5):1187-1198
2. Reddy KB,Nabha SM,Atanaskova N,et al.Role of MAP kinase in tumor progression and invasion,2003,22(4):395-403
3. Phillips RA,Hunter JL,Eccleston JF,et al.The mechanism of Ras GTPase activation by neurofibromin,2003,42(13):3956-65.
4. Asha H,Nagy I,Kovacs G,etal.Analysis of Ras-induced overproliferation in Drosophila hemocytes,Genetics,2003,163:203-215
5. Bivona TQPerez De,Castro I,et al.Phospholipase Cgamma activates Ras on the Golgi apparatus by means of RasGRP1.Nature,2003,424:694
6. McKenna WG,Muschel RJ,Gupta AK,et al.The RAS signal transduction pathway and its role in radiation sensitivity.Oncogene,2003,22(37):5866.
7. Kolch W,Biochem J.Meaningful relationships:the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions.2000,351 (2):289-305.
8. Hilger RA,Scheulen ME,Strumberg D.The Ras-Raf-MEK-ERK pathway in the treatment of cancer.Oncology,2002,25:511-518
9. Davis RJ.Signal transduction by the JNK group of MAP kinases.Cell,2000,103:239-252
10.刘秉文,陈俊杰.医学分子生物学.北京：中国协和医科大学出版社,2005,131-197
11. Mavria G,Vercoulen Y,Yeo M,et al.ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis.Cancer Cell,2006,9(1):33-44.
12. David M,Petricoin E,Benjamin C,et al.Requirement for MAP kinase(ERK2) activity in interferon-x and interferon-x-stimulated gene expression through STAT proteins. Science,1995,269:1721-1723.
13. WidmannC,Gibosn S,Jarpe MB,et al.Mitrogen-activated protein kinase conservation of a three-kinase module from yeast to human.Physiol Rev,1999,79(1):143-180
1. 高润霖,吴宁,胡大一.心血管病治疗指南和建议.北京：人民军医出版社,2005：1
2. 陈可冀,雷燕.加强不稳定性心绞痛的防治研究[J].中国中西医结合杂志,1996,16(10)：579
3. 雷燕,陈可冀,柯元南,等.愈心痛胶囊治疗不稳定性心绞痛临床研究[J].中国中西医结合杂志,1996,16(10)：580-583
4. 李松林,罗纯.通心络胶囊治疗不稳定性心绞痛疗效分析[J].医学文选,2000,19(2)：208
5. 金露.复方丹参滴丸对冠心病不稳定性心绞痛患者血小板活化功能的影响[J].中国中西医结合杂志,2000,20(6)：415-417
6. 王听.复方丹参滴丸治疗不稳定性心绞痛疗效观察[J].解放军药学学报,2001,17(2)：78-80
7. 李如兰.通心络治疗不稳定性心绞痛34例[J].中国中医急症,2001,10(2)：107-108
8. 杨丁友,段学忠,周次清.舒心益脉胶囊对冠心病不稳定性心绞痛患者血小板活化功能的影响[J].中国实验方剂学杂志,2001,7(4)：50-51
9.平玉兰.复方丹参含片治疗不稳定性心绞痛76例[J].河南医药信息,2002,10(6)：6-9
10.苏玉国.中西医结合治疗不稳定性心绞痛疗效观察[J].山西中医,2004,20(4)：27-28
11.李亚秋.步长稳心颗粒联合常规用药治疗不稳定性心绞痛[J].中国实用医药,2008,3(5)：62-63
12.孙丽,张慧恩,郭晓玲,等.步长稳心颗粒治疗不稳定性心绞痛的疗效观察[J].中国现代药物应用,2008,2(17)：53
13.郭志忠,郭红星,郭显玲.中西医结合治疗不稳定性心绞痛90例疗效观察[J].中国中西医结合民间疗法,2008,2：18
14.孙朝阳,侯玉娟,苏旻.通心络胶囊联合低分子肝素钠治疗不稳定性心绞痛50
例[J].方药应用中国民间疗法,2008,11：33-34
15.张艳霞,陈桂玲.通心络对不稳定性心绞痛血浆内皮素的影响及疗效观察[J].中国中医药现代远程教育,2008,6(5)：441-442
16.王萍.中西医结合治疗老年不稳定性心绞痛临床观察[J].湖北中医杂志,2009,31(2)：32-33
17.马建平.通心络胶囊治疗不稳定性心绞痛28例[J].方药应用中国民间疗法,2009,17(9)：39
18.郑国玲,王盛华.血府逐瘀胶囊治疗不稳定性心绞痛的临床疗效观察及机制探讨[J],2009,29(1)：65-68
19.张静,李国武.通心络胶囊治疗不稳定性心绞痛的疗效观察[J].西部医学,2009,21(8)：1352-1353
20.邢雁伟,王阶,衷敬柏,等.采用聚类分析和对应相关方法研究1069例冠心病心绞痛证候应证组合规律[J].中华中医药杂志,2007,22(11)：747-750
21. Lush TF, Wenzel RR. Endothelial and endothelin antagonisis pharmacology and clinical implication[J].Agents Actions Suppl,1995,45:237
22.张静,张菲斐.心绞痛患者血小板α颗粒膜蛋白及D-二聚体的变化[J].中华内科杂志,1999,38(8)：527-529
23.吴国新,阮长耿.血小板颗粒膜蛋白研究进展[J].中华血液学杂志,1994,15(3)：162-164
1.胡大一,马长生.心脏病学实践2008-规范化治疗[M].北京：人民卫生出版社,2009,3
2. Engerman RL,Pfaffenbach D,Davis MD.Cell turnover of capillaries.Lab Invest,1967,17(6):738-743.
3. Judah Folkman.Angiogenesis in cancer vascular rheumatoid and other disease. Nature Medicine,1995,1:27-30
4. Folkman J.Angiogenesis[J].Annu Rev Med,2006(57):1-18
5. Hanahand,Folkman J.Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.Cell,1996,86(3):353-364
6. SchaperW,ItoWD.Molecular mechanisms of cornonary collateral vessel growth[J].Cire Res,1996,79(5):911-919
7. Neufeld QKessler O,Herzog Y.The interaction of Neuropilin-1 and Neuropilin-2 with tyrosine-kinase receptors for VEGF.Adv Exp Med Biol,2002,515:81-90
8. Thurston G,Rudge JS,Ioffe E,et al.Nat Med,2000,6(4):460-463
9. Kobayashi H,Lin PC.Angiopoietin/Tie2 signaling tumor angiogenesis and inflammatory diseases.Front Biosci,2005,10:666-74
10. Plank MJ,Sleeman BD,Jones PF.The Role of the Angiopoietins in tumour angiogenesis.Growth Factors,2004,22:1-11
11. Metheny-barlow LJ,LI LY.The enigmatic role of the angiopoietins in tumour
angiogenesis.Cell Res,2003,13:309-317
12. Fan TPD,Jaggar R,Bicknell R.Controlling the vasculature:Angiogenesis anti-angiogenesis and vascular targeting of gene therapy.Trends Pharmacol Sci,1995,16(2):57-66
13. Itch T,Tanioka M,Yoshida H,et al.Reduced angiogenesis and tumor progression in gelatinase A-deficient mice.Cancer Res,1998,58(5):1048-051
14. Ehringer WD, Wang OL, Haq A, Miller FN. Bradykinin and a-thromb increase human umbilical vein endothelial macromolecular permeability by different mechanisms.Inflammation,2000,24(2):175-193
15. Bellon QMartiny L,Robinet A.Matrix metalloproteinases and matrikinesin angiogenesis.Crit Rev Oncel Hematol,2004,49(3):203-220
16. Harada K,Friedman M,Lopez JJ,etal.Vascular endothelial growth administration in chronic myocardial ischemia[J].Am J Physiol,1996,270(5Pt2):H1719
17. Schaper W,Buschmann I.Arteriogenesis,the good and bad of it.Cardiovasc Res,1999,43(4):835-837
18. Plate KH,Breior QWeich HA,et al.angiogenesis:Molecule and mode.Nature,1992,359:845-848
19. Ausprunk DH,Folkman J.Migration and proliferation of endothelial cells in performed and newly formed blood vessels during tumor angiogenesis.Microvasc Res,1977,14:53.
21. Folktnan J.Haudenschild, C.Natute,1980,288:551-556.
23. D'Amore PA.Capillary Growth:a two cell syssterm.Semin Cancer Biol,1992,3:49.
24. Plate KH,Breior G,Weich HA,et al.angiogenesis:Molecule and mode.Nature,1992,359:845-848
25.刘启功,王琳,陆再英,等.葛根素对心肌梗塞犬冠脉侧枝循环的影响.中国中药
杂志,1999,24(5)：304-306.
26.关国跃,石耀辉,唐丕玉.葛根素改善缺血性心肌血流灌注的探讨.心血管康复医学杂志,2001,10(1)：71-72.
27.刘启功,王琳,陆再英,等.丹参注射液对犬缺血心肌更新供血的影响.中国医院药学杂志,1999,19(11)：653-655.
28.刘启功,孙玉梅,程燕子等.丹参限制犬心肌梗死范围及其机制的研究.中国现代医学杂志,2005,15(15)：2257-2259
29.吴旭,晋军,梁自文,等.蜕皮甾酮对冠状动脉闭塞致大鼠心肌梗死的有益作用及机制.中草药,2001,32(8)：721-723.
30.李朝武,刘新泳,张蕊等.川芎醇对血管内皮细胞增殖与损伤保护作用的研究.山东大学学报(医学版).2003,41(4)：402-407.
31.刘新泳,赵全芹,李朝武等.川芎咔啉碱的合成及其对血管内皮细胞损伤的保护作用.山东大学学报(医学版),2003,41(5)：485-487
32..李剑,范维琥,敖红,等.中药红景天对大鼠缺血心肌Flt1、KDR及Tie2表达的影响.中国中西医结合杂志,2005,25(5)：445-448
33.李剑,范维琥,罗心平,等.预灌红景天对心梗大鼠心功能Flk-1mRNA表达的影响.复旦学报(医学版),2006,33(3)：384-387
34.雷燕,王军辉,陈可冀.黄芪、当归配伍后促鸡胚绒毛尿囊膜血管生成的药效比较研究.中国中药杂志,2003,28(9)：876-878.
35.雷燕,高倩,李悦山,等.黄芪、当归及其组方促血管内皮细胞增殖作用的研究.中国中西医结合杂志,2003,23(10)：753-756.
36.雷燕,王培利,林燕林,等.当归补血汤煎剂对实验性心肌梗死衰老大鼠缺血心肌的促血管生成作用.中国中医基础医学杂志,2005,11(12)：892-894.
37.王培利,雷燕,林燕林等.当归补血汤含药血清对培养内皮细胞生长因子受体表达的影响.中西医结合心脑血管病杂志,2006,4(3)：209-212.
38.孟君,冯君.心脉通胶囊对急性心肌梗死病人血管内皮生长因子表达的影响.广州中医药大学学报,2002,19(2)：88-89
39.汪姗姗,李勇,范维琥,等.麝香保心丸对实验性心肌梗塞大鼠心脏的促血管生成作用.中成药,2002,24(6)：446-449.
40.汪姗姗,李勇,范维琥等.麝香保心丸对鸡胚绒毛尿囊膜及培养的血管内皮细胞的促血管生成作用.中国中西医结合杂志.2003,23(2)：128-131
41.杨祖福,胡婉英,秦志强,等.双龙丸对大鼠实验性心肌梗死血管新生的影响与分子学机制.中国康复理论与实践,2003,9(5)：293-295
42.王文健,傅晓东,陈伟华等.通心络促血管新生作用的实验研究.疑难病杂志,2003,2(1)：2-4
43.韩丽华,王振涛,索红亮,等.益气活血方促心梗后大鼠缺血心肌血管新生的实验研究.河南中医,2005,25(11)：21-23
44.张宗棨,邢之华,唐涛,等保心汤对心肌梗死PTCA患者血清VEGF的影响.北京中医药大学学报,2006,29(4)：277-280
45.尹慧秋,张继东,林海青,等舒脉胶囊对大鼠缺血心肌促血管新生的影响.中国中西医结合杂志,2007,27(11)：1020-1022
46.冯玲,曹洪欣,胡元会,等.温阳益心方对大鼠心肌梗死模型心肌梗死面积及梗死边缘区血管密度的影响.中西医结合心脑血管杂志,2009,7(2)：165-166
1. Pradeep CR, Sunila ES, Kuttan G.Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.Integrative cancer therapies,2005,4 (4):315-321
2. Senger DR, Galli SJ, Dvorak AM.Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.Science,1983,219:983-985
3. Ferrara N,Henzel WJ.Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.Biochem Biophys Res Commun,1989,161(2):851-858.
4. Ueda M,Terai Y,Kumagai K.Vascular endothelial growth factor C gene expression is closely related to invasion phenotype in gynecological tumor cells.Gynecol Oncol,2001,82(1):162-166
5. Brown LF,Detmar M,Claffey K,et al. Vasclular permeability factor/vascular endothelial growth factor:a multifunctional angiogenic cytokine.Hum Genet.1997,79:233
6. Akagi K,Ikeda Y,Miyazaki M,et al.Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues.Br J Cancer,2000,83(7):887-891.
7.陈治,杜钰.血管内皮细胞特异性受体在肿瘤血管靶向治疗中的应用.世界华人消化杂志,2001,9(6)：702-705
8. Zeng H,Dvorak HF,Mukhopadhyay D. Vascular permeability factor (VPF)/vascular endothelial growth factor (VEGF) peceptor-1 down-modulates VPF/VEGF receptor-2 mediated endothelial cell proliferation,but not migration,through phosphatidylinositol 3-kinase-dependent pathways.J Bio Chem,2001,276(29):26969-26979.
9. Soker S,Takashima S,Miao HQ,et al.Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.Cell,1998,92:735-745
10. Ferrara N,Davis-Smyth.The biology of vascular endothelial growth factor.Endocr Rev,1997,18:4-25
11. Lebherz C,Degenfeld G,Karl A,et al.Therapeutic angiogenesis/arteriogenesis in the chronic ischemic rabbit hindlimb:effect of venous basic fibroblast growth factor retroinfusion,2003,10:257-265
12. Gerber HP,McMurtrey A,Kowalski J,et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway requirement for Flk-1/KDR action.J Biol Chem,1998,273:30336-30343
13. Gerber HP, Hillan KJ,Ryan AM,et al. VEGF is required for growth and survival in neonatal mice.Development,1999,126:1149-1159
14. de Vries C,Escobedo JA, Ueno H. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science,1992,255:989-991
15. Andrew P,Levy NS,Levy JL,et al.Regulation of vascular endothelial growth factor in cardiac myocytes.Circ Res,1995,76(5):758-766.
16. Ariadne M,john T,Anastasia T,et al. Changes in serum levels of vascular endothelial growth factor in males and females throughout life.Soc Gynecol Investing,2000,7(5):309-312
17. Duyndam MC,Hilhorst MC,Schluper HM, et al. Vascular endothelial growth factor-165 overexpression stimulates angiogenesis and induces cyst formation and macrophage infiltration in human ovarian cancer xenografts. Am J Patho,2002,160(2):537-548
18.周泉.血管内皮生长因子的生物学特性及临床研究进展[J].实用心脑肺血管病杂志,2001,9(1)：51-54.
19. Muklerjee S,Tessema M,Wandinger—Ness A.Vesicular trafficking of tyrosine kinase receptors and associated proteins in the regulation of signaling and vascular function[J].Cire Res,2006,98(6):743-756
20. LeeSH,WolfPL,EseuderoR,etal.Early expression of angiogenesis factoes in acute myocardial ischemia and infarction[J].N Engl J Med,2000,342(2):1487-1493
21. Rak J,Yu JL,Kiement G,et al.Oncogenes and angiogenesis:signaling three-dimensional umor growth.Investing Dermathol Symp Proc,2000,5(1):24-33
22. Strohmeyer D,Rossing C,Bauerfeind A,et al.Vascular endothelial growth factor and its correlation with angiogenesis and P53 expression in protate cancer[J]. Prostate,2000,45 (3):216-224.
23. Frank S,Hubner QBreier G,et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J Biol Chem,270,12607-12613
24. Brogi E,Wu T,Namiki A,et al. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression invascular smooth muscle cells,whereas hypoxia upregulates VEGF expression only. Circulation,1994,90:649-652
25. HaradaK,Friedman m,.Lopez JJ.Vascwlar endothelial growth factor admimistration in chronic myocardial ischemia.Am Journal Physnol,1996,270:1791-802
26. Sato K, Wu T, Laham RJ,et al.Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia,J Am Coll Cardiol,2001,37(2):616-623.
27. Zhou ZM.Debabrata M.Wang K Induction of angiogenesis in a canine model of chronic myocardial ischemia with intravenous infusion of Vascular Endothelial Growth Factor(VEGF) combined with ultrasound energy and echo contrast agent. J Am Coll Cardiol,2002,39(Supplement2):396
28. Rutanen J,Rissanen TT,Markkanen JE,et al.Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation, 2004,109(8):1029-1035
29. Muhlhanser J,Merrill MJ,Pili R.VEGF165 expressed by a rephication deficient recombinant adenoviras rector induces angiogenesis in vivo.Circ Res,1995, 77:1077-1086
30. Lee LY,Patel SR,Hackett NR,et al.Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial gronth factor 121.Ann Thorac Surg,2000,69:14-24
31. Kornowski R,Leon MB,Fuchs S,et al.Electromagnetic guidance for catheter-based transendocardial injection:a platform for intramyocardial angiogenesis therapy. Results in normal and ischemic porcine models.J Am CollCardiol,2000,35:1031-1039
32. Schalch P,Rahman GF,Patejunas G,et al. Adenoviral-mediated transfer of vascular endothelial growth factor 121 cDNA enhances myocardial perfusion and exercise performance in the nonischemic state.J Thorac Cardiovasc Surg,2004,127:535-540
33. Suzuki K,Murtuza B,Smolenski RT.Cell transplatation for treatment of myocardial infarction using vascular endothelial growth factor-expressing skeletal myoblasts.Circulation,2001,9(104):207-212
34. Xiaojin H,Agneta M B,et al.Myocardial angiogenesis after plasmid or adenoviral VEGF-A 165 gene transfer in rat myocardial infraction.Model.Cardio Res,2007,73:481
35. Douglas W,Losordo DW,Vale PR, et al.Gene therapy for myocardial injection of phVEGF165 as sole therapy for myocardial ischemia.[J].Circulation,1998,98(12): 2800-2804.
36. Rosengart TK,Lee LY,Patel SR,et al.Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA[J].A nn Surg,1999,230(4):466-470
37..Symes JF,.Losordo DW,Vale PR,et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg,1999,68:830-836
38. Henry TD, Annex BH,McKendall GR,et al. The VIVA trial:Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation,2003,107:1359-1365
39. Losordo DW,Vale PR, Hendel RC,et al.Phase 1/2 placebo-controlled, double-blind,dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia.Circulation,2002,105:2012-2018
40. Amerian Heart Association. Amerian Heart Association's Top 10 research advances for 2001 include heart device,cell transplants and drug-eluting stents.2001 Year-end Report,2001
41. Schwarz E R,Speakman M T,Patterson M,et al.Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor(VECF)in a myocardial infarction model in the rat-angiogenesis and angioma formation.J Am Coll Cardiol,2000.35(5):1323
1. Fonsatti E,Jekunen AP,Kairemo KJ,et al.Endoglin is a suitable target for efficient imaging of solid tumors:in vivo evidence in a canine mammary carcinoma model.Clinical cancer research,2000,6(5):2037-2043
2. Quackenbush EJ,Letarte M.Identification of several cell surface proteins of non-T,non-B acute lymphoblastic leukemia by using monoclonal antibodies.J Immunol,1985,134(2):1276-1285.
3. Gougos A,Letarte M.Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line.J Immunol,1988,141(6):1925-1933.
4. Gougos A,Letarte M.Biochemical characterization of the 44G4 antigen from the HOON pre-B leukemic cell line.J Immunol,1988,141(6):1934-1940
5.金伯泉主编.细胞和分子免疫学[M].上海世界图书出版公司,1995,2-3.
6. Haruta Y,Seon BK.Distinct human leukemia-associated cell surface glycoprotein GP160 defined by monoclonal antibody SN6.Proc Nati Acad Sci USA,1986,63:7898-7902
7. Fernandez-Ruiz E,St-Jacques S,Bellon T,et al.Assignment of the human endoglin gene (END) to 9q34→qter [J]. Cytogenet Cell Genet,1993,64:204.
8. Pichuantes S,Vera S,Bourdeau A,et al.Mapping epitopes to distinct regions of the extracellular domain of endoglin using bacterially expressed recombinant fragments.Tissue Antigens,1997,50:265-276.
9. ParkerJ.M.R,Guo Dand Hodges R.S.New hydrophilicity scale derived from high-performance liquid chromatography peptide retention data:correlation of predicted surface residues with antigenicity and x-ray-derived accessible sites. J Biochem,1986,25(19):5425-5432.
10. Yamashita H,Ichijo H,Grimsby S,et al.Endoglin forms a heteromeric complex with the signaling receptors for transforming growth factor-beta.J Biol Chem,1994,269(3):1995-2001.
11. Fonsatti E,Del Vecchio L,Altomonte M,et al.Endoglin:An accessory component of the TGF-beta-binding receptor-complex with diagnostic,prognostic,and bioimmunotherapeutic potential in human malignancies.J Cell Physiol,2001,188(1):1-7.
12. Cheifetz S,Hernandez H,Laiho M,et al.Distinct transforming growth factor-β (TGF-β)receptor subsets as determination of cellular responsiveness to three TGF-β isforms. J BiolChem,1990,265:20533-20538.
13. Cheifetz S,Bellon T,Cales C,etal.Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells.Biol Chem,1992,267:19027-19030.
14. Guerrero-Esteo M,Sanchez-Elsner T,Letamendia A,et al.Extra cellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors Ⅰ and Ⅱ [J].J Biol Chem,2002,277 (32):29197-29209.
15. Lastres P,Letamendia A,Zhang H,et al.Endoglin modulates cellular responses to TGF-beta 1 [J].J Cell Biol,1996,133(5):1109-1121.
16. Wahl SM.Transforming Growth Factor:The Good,the Bad and the Ugly.J Exp Med,1994,180(5):1587-1590.
17. Heldin CH,Miyazono K,Ten Dijke P.TGF-beta signaling from cell membrane to nucleus through SMAD proteins [J].Nature(London),1991,390:465-471.
18. Lastres P,Letamendia A, Zhang H,et al.Endoglin modulates cellular responses to TGF-beta 1 [J].J Cell Biol,1996,133(5):1109-1121.
19. Li C,Guo B,Wilson PB,et al. Plasma levels of soluble CD 105 correlate with metastasis in patients with breast cancer. Int J Cancer,2000,89(2):122-126.
20. Li C,Hampson IN,Hampson L,et al.CD105 antagonizes the inhibitory signaling of transforming growth factor betal on human vascular endothelial cells [J].FASEB J,2000,14(1):55-64.
21. Bourdeau A,Faughnan ME,Letarte M.Endoglin-deficient Mice,a unique model to study hereditary hemorrhagic telangiectasia.Trends Cardiovasc Med,2000,10(7):279-285
22..Dickson MC,Martin JS,Cousins FM,et al.Defective haematopoiesis and vasculogenesis in transforming growth factor-1 knock out mice. Development,1995,121:1845-1854
23. Li DY,Sorensen LK,Brooke BS,et al.Defective angiogenesis in mice lacking endoglin. Science,1999,284(5419):1534-1537.
24. Bourdeau A,Dumont DJ,Letarte M,et al.A murine model of hereditary hemorrhagic telangiectasia. J ClinInvest,1999,104(10):1343-1351.
25. van den Driesche S, Mummery CL, Westermann CJ. Hereditary hemorrhagic telangiectasia:an update on transforming growth factor beta signaling in vasculogenesis and angiogenesis.Cardiovasc Res,2003,58(1):20-31
26. Kim YJ,Varki NM,Varki A,et al.P-selectin deficiency attenuates tumor growth and metastasis. Proc NatI Acad Sci USA,1998,95(16):9325-9330
27. Miller DW,Graulich W,Karges B,et al.Elevated expression of endoglin,a component of the TGF-beta-receptor complex,correlates with proliferation of tumor endothelial cell. Int J Cancer,1999,81(4):568-572
28. Wikstrom P,Lissbrant IF,Stattin P,et al.Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate, 2002,51(4):268-275
29. Warrington K,Hillarby MC,Li C,et al.Funtional role of CD105 in TGF-betal signalling in murine and human endothelial cells[J].Anticancer Res,2005, 25(3B)：1851-1864
30.崔松,吕树铮,陈韵岱,等.冠心病患者可溶性CD105与hs-CRP水平相关分析.心肺血管杂志,2008,27(2)：75-78
31. Bodey B,Bodey JR,Siegeal SE,et al. Over-expression of endoglin (CD105):a marker of breast carcinoma-induced neo-vascularization.Anticancer Res,1998,18(5A):3621-3628.
32. Tanaka F,Otake Y,Yanagihara K,et al. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer:comparison between CD 105 and CD34 as a marker of angiogenesis.Lung Cancer,2003,39(3):289-296
33. Saad RS,Jasnosz KM,Tung MY,et al. Endoglin (CD105) Expression in Endometrial Carcinoma.Int J Gyneocol Pathol,2003,22(3):248-253
34.李大林,李杨,李传祖等.CD 105和VEGF在大肠癌新生血管中的表达.中国普痛外科杂志,2003,12(11)：815-818
35. Pang D,Liu F,Xue YW,et al. Clinicopathologic significance of CD105 mRNA expression in human breast carcinoma[J].Zhong hua Zhong Liu Za Zhi,2005,27(1):38-40.
36. Chien CY,Su CY,Hwang CF,et al.Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx[J].Head Neck,2006,28(5):441-446
37. Kyzas PA,Agnantis NJ,Stefanou D.Endoglin (CD105) as a prognostic factor in head and neck squamous cell carcinoma. Virchows Archiv,2006,448(6):768-775